Mapping the Healthcare Landscape: Bringing pharmaceuticals into focus

Courtesy of the patent cliff, the pharmaceutical industry is set for a dramatic slow down in revenue growth from 2011. Industry players are therefore looking to implement strategies which will cushion them against the anticipated revenue short-fall, with diversification away from pharmaceuticals into other healthcare sectors one avenue under consideration.

Claim "10% Discount for Farmavita.Net Members" when purchasing this report!

Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan

Over the past decade, vaccines have resurfaced as an attractive commercial proposition for Pharma. The developed world has been the initial focus of vaccine makers due to the better healthcare infrastructure and higher price levels. However, facing increasingly saturated markets in the West, companies are looking to expand into new geographies, such as Asia's emerging markets.

Influenza Vaccines and Antivirals - The pandemic's long-term impact

Fuelled by the pandemic flu threat, the influenza market has expanded rapidly in recent years. This growing commercial opportunity has encouraged companies to develop new technologies and increase manufacturing capacity for influenza vaccines and antivirals. The H1N1 pandemic will stimulate further growth, but also confronts industry and public health stakeholders with new challenges.

The Diabetes Market Outlook to 2011

The Diabetes Market Outlook to 2011 provides in-depth insights into new product launches, upcoming patent expiries and on-going clinical trials in order to predict changes in global market dynamics. Key R&D trends are analyzed and pipeline compounds of the top players are evaluated, enabling you to strengthen your position in the diabetes market and anticipate future product success.

Molecular Targeted Cancer Therapies - Leading companies will hold onto competitive advantage in high growth market

Molecular targeted cancer therapies are the biggest and fastest growing class of cancer drugs in terms of sales. As growth of revenues from cytotoxic therapies and antihormonal therapies has slowed and many key brands in these classes face imminent patent expiries, it is unsurprising that the major oncology companies have shifted their focus towards the molecular targeted cancer therapies market.

Top 20 Cancer Therapy Brands - Targeted therapies will drive market growth in the wake of the cytotoxic and antihormonal patent cliff

The cancer therapies market offers a high level of commercial reward to a handful of companies including Roche, Sanofi-Aventis, AstraZeneca, Novartis and Eli Lilly. Cancer therapy sales totaled over $38 billion in the seven major pharmaceutical markets in 2008, growing at a CAGR of 17.4% between 2005 and 2008.

Colorectal Cancer - Shaping the future dynamics of colorectal cancer management

Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard therapy. The advent of Avastin and Erbitux heralded a new era in the disease management, and the emergence of other molecular targeted agents should further push survival to an unprecedented level in the coming years.

Biotech in the New EU Member States: Policy Recommendations

The study carried-out on the development status and capacity of healthcare biotechnology in the new EU Member States and candidate countries shows a much contrasted picture of biotechnology development in this region. Each country has a different economic development strategy and a unique history and capacity in the life-science and healthcare sector which determines its path to development. Based on these observations, it would be unsuitable to propose general recommendations in a sort of unique formula to build or develop a healthy healthcare biotechnology sector.

Donwnload free 14 pages report at our Download Section.

Biotech in the New EU Member States: an Emerging Sector

This report is the first of its kind to try and understand the state of the biotechnology industry in the new Member States and candidate countries. As with any bottom-up work, it took a lot of effort and persistence to gather data on current and prospective developments in this area. Our goal was to strengthen the understanding of the European biotechnology scene and we believe that with the knowledge accumulated we have reached this goal. This report should enable policy makers and investors to make informed decisions about biotechnology support and development. The databases developed during this project will also provide better international visibility to the companies, which could lead to new cooperation or investment.

Donwnload free 33 pages report at our Download Section.

Community Antibacterials - Pipelines wither as generic tidal wave takes its toll

Datamonitor research points to this sector, beleaguered by patent expiries, barriers to market entry and uptake, becoming increasingly inclement towards branded drugs. Generic incursion has taken a heavy toll on the market at a number of levels. The volume of key brands facing generic competition makes it even harder for remaining products to court large revenues in the community sector.

Molecular systems to open new markets

As a result of the increasing switch from live-attenuated and killed whole-cell vaccines to subunit antigens, there is a need for novel antigen delivery technologies to improve vaccine efficacy and safety. This report assesses key strategies, technologies and products for vaccine antigen delivery. It provides an overview of opportunities and challenges for the sector and a future outlook.

New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency

With industry consolidation, the economic downturn, and an increasing threat from generics, pharma companies are coming under greater pressure to fill their pipelines with innovative drugs. However, despite the costs and risks involved in drug development, the pharma industry is finding new ways to streamline the R&D process in an effort to increase efficiency and output.

Osteoporosis - Novel agents to battle for payer acceptance

Osteoporosis continues to be an attractive therapy area for large pharmaceutical companies due to its high prevalence rate and unmet need. Globally, sales for osteoporosis drugs grew 7.0% year-on-year from 2004 to $9.6 billion in 2008 driven by strong performance of the bisphosphonate class.

Acute Leukemias - Persistent unmet needs confer significant commercial opportunity

While existing treatment strategies for adult acute leukemia may yield satisfactory remission- induction rates, a major clinical concern is the high rate of disease relapse despite attempts to optimize post-remission consolidation therapy. This is acutely problematic among elderly patients who are frequently unable to tolerate the rigors of more intensive treatment approaches.

Chronic Leukemias - Is there room left for improvement?

CLL is the most common form of leukemia in western countries. Recent therapeutic advances have improved the rate and duration of remission, although there is no consensus over the optimum regimen. CML has a lower incidence than CLL, but is a commercially lucrative indication for Gleevec (imatinib; Novartis) which continues to enjoy blockbuster success, having revolutionized the treatment of CML.

Genzyme Corporation: PharmaVitae Profile

This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical sector.

The Cardiovascular Market Outlook to 2013: Competitive landscape, global market analysis and pipeline analysis

This report provides comprehensive coverage of every class of drugs across major cardiovascular indications and profiles the underlying trends and factors driving the market. Detailed insights into recent key events and future market leaders are also provided, in addition to epidemiological analysis and forecasts for major products over the 2007-13 period.

Diabetes to the fore as generics hit primary care markets

Datamonitor expects antidiabetic therapies to emerge as the biggest revenue earner in the cardiovascular and metabolic markets by 2017. A large and diverse development pipeline will provide a number of new blockbuster drugs but the heavy genericization of the hypertension and dyslipidemia primary care markets will lead to the overall market only growing by 0.9% in the seven major markets.